The DOI matches its Crossref record; 31 of the 33 references it cites were found in a registry or an index.
Radiation Dosimetry for 177 Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions
Open accessAbstract
Prostate-specific membrane antigen (PSMA)–targeted radioligand therapy is increasingly used in metastatic castration-resistant prostate cancer. We aimed to estimate the absorbed doses for normal organs and tumor lesions using 177Lu-PSMA I&T (I&T is imaging and therapy) in patients undergoing up to 4 cycles of radioligand therapy. Results were compared with pretherapeutic Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBEDCC)] (68Ga-PSMA-HBED-CC) PET. Methods: A total of 34 cycles in 18 patients were analyzed retrospectively. In 15 patients the first, in 9 the second, in 5 the third, and in 5 the fourth cycle was analyzed, respectively. Whole-body scintigraphy was performed at least between 30–120 min, 24 h, and 6–8 d after administration. Regions of interest covering the whole body, organs, and up to 4 tumor lesions were drawn. Organ and tumor masses were derived from pretherapeutic 68Ga-PSMA-HBED-CC PET/CT. Absorbed doses for individual cycles were calculated using OLINDA/EXM. SUVs from pretherapeutic PET were compared with absorbed doses and with change of SUV. Results: The mean whole-body effective dose for all cycles was 0.06 ± 0.03 Sv/GBq. The mean absorbed organ doses were 0.72 ± 0.21 Gy/GBq for the kidneys; 0.12 ± 0.06 Gy/GBq for the liver; and 0.55 ± 0.14 Gy/GBq for the parotid, 0.64 ± 0.40 Gy/GBq for the submandibular, and 3.8 ± 1.4 Gy/GBq for the lacrimal glands. Absorbed organ doses were relatively constant among the 4 different cycles. Tumor lesions received a mean absorbed dose per cycle of 3.2 ± 2.6 Gy/GBq (range, 0.22–12 Gy/GBq). Doses to tumor lesions gradually decreased, with 3.5 ± 2.9 Gy/GBq for the first, 3.3 ± 2.5 Gy/GBq for the second, 2.7 ± 2.3 Gy/GBq for the third, and 2.4 ± 2.2 Gy/GBq for the fourth cycle. SUVs of pretherapeutic PET moderately correlated with absorbed dose (r = 0.44, P < 0.001 for SUVmax; r = 0.43, P < 0.001 for SUVmean) and moderately correlated with the change of SUV (r = 0.478, P < 0.001 for SUVmax, and r = 0.50, P < 0.001 for SUVmean). Conclusion: Organ- and tumor-absorbed doses for 177Lu-PSMA I&T are comparable to recent reports and complement these with information on an excellent correlation between the 4 therapy cycles. With the kidneys representing the critical organ, a cumulative activity of 40 GBq of 177Lu-PSMA I&T appears to be safe and justifiable. The correlation between pretherapeutic SUV and absorbed tumor dose emphasizes the need for PSMA-ligand PET imaging for patient selection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The dosimetry studies of small molecules targeting PSMA such as 124 I/ 131 I-MIP-1095, or 177 Lu-PSMA-617 or 177 Lu-PSMA I&T have shown salivary glands commonly receive the highest radiation-absorbed dose among normal organs ( 69 , 74 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [74]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tolerance of normal tissue to therapeutic irradiation
Emami, B., Lyman, J., Brown, A., Cola, L., Goitein, M., Munzenrider, J. E., Shank, B., Solin, L. J., & Wesson, M. (1991) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(91)90171-y · Cited by 4,488
International Variation in Prostate Cancer Incidence and Mortality Rates
Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012) · European Urology · doi:10.1016/j.eururo.2012.02.054 · Cited by 1,521
Eiber, M. J., Maurer, T., Souvatzoglou, M., Beer, A. J., Ruffani, A., Haller, B., Graner, F.-P., Kübler, H. R., Haberhorn, U., Eisenhut, M., et al. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.154153 · Cited by 995
Self-citationAfshar‐Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H., Hadaschik, B. A., Holland‐Letz, T., Giesel, F. L., Kratochwil, C., Haufe, S., et al. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2298-2 · Cited by 919
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., & Krenning, E. P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.08.066 · Cited by 657
Kratochwil, C., Giesel, F. L., Stefanova, M., Benešová, M., Bronzel, M., Afshar-Oromieh, A., Mier, W., Eder, M., Kopka, K., & Haberkorn, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171397 · Cited by 636
Kinahan, P. E., & Fletcher, J. W. (2010) · Seminars in Ultrasound, CT and MRI · doi:10.1053/j.sult.2010.10.001 · Cited by 631
Siegel, J. A., Thomas, S. R., Stubbs, J. B., Mg, S., Hays, M. T., Koral, K. F., Robertson, J. S., Howell, R. W., Wessels, B. W., Fisher, D. R., et al. (1999) · PubMed · Cited by 572
Baum, R. P., Kulkarni, H., Schuchardt, C., Singh, A., Wirtz, M., Wiessalla, S., Schottelius, M., Müeller, D., Klette, I., & Wester, H. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.168443 · Cited by 532
Self-citationProstate-specific membrane antigen expression as a predictor of prostate cancer progression
Perner, S., Hofer, M. D., Kim, R., Shah, R. B., Li, H., Mӧller, P., Hautmann, R. E., Gschwend, J. E., Kuefer, R., & Rubin, M. A. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.11.012 · Cited by 455
Cited by
Sorted by citations
Items 201–213 of 213
Siebinga, H., de Wit-van der Veen, B. J., de Vries–Huizing, D. M. V., Vogel, W. V., Hendrikx, J. J. M. A., & Huitema, A. D. R. (2024) · Figshare · doi:10.6084/m9.figshare.26711045
Salas-Ramirez, M., Leube, J., Lassmann, M., & Tran‐Gia, J. (2024) · Figshare · doi:10.6084/m9.figshare.25294654
Resch, S., Fouladgar, S. T., Zacherl, M., Sheikh, G. T., Liubchenko, G., Rumiantcev, M., Unterrainer, L. M., Wenter, V., Bartenstein, P., Ziegler, S. I., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22606406
Self-citationKarimzadeh, A., Schatz, L., Sauer, M., Apostolova, I. I., Buchert, R., Klutmann, S., & Lehnert, W. (2024) · Figshare · doi:10.6084/m9.figshare.26750252
Salas-Ramirez, M., Leube, J., Lassmann, M., & Tran‐Gia, J. (2024) · Figshare · doi:10.6084/m9.figshare.25294837
Salas-Ramirez, M., Leube, J., Lassmann, M., & Tran‐Gia, J. (2024) · Figshare · doi:10.6084/m9.figshare.26685639
Winter, E., Rettner, K., Schroth, D., Liermann, J., Herfarth, K., Debus, J., Haberkorn, U., Kratochwil, C., & Koerber, S. A. (2025) · ARC Journal of Urology · doi:10.20431/2456-060x.0901005
Prostate cancer: prospects of radionuclide therapy: literature review
Vasiliev, A. A., Kukosh, M. Y., Simonyan, A. M., & Makeev, V. A. (2026) · Medical alphabet · doi:10.33667/2078-5631-2025-33-22-31
Khreish, F., Rosar, F., Burgard, C., Petto, S., Maus, S., Stemler, T., Bartholomä, M. D., Sabet, A., Schaefer-Schuler, A., & Ezziddin, S. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01394-z
Nikiforuk, A. I., Khalimon, A. I., Shakirova, A., Lokhova, A. V., Bagaturya, V., Baltabaev, I., Khodzhibekova, M. M., Khamadeeva, G. F., Khodakova, D. Y., Лазутина, Т. Н., et al. (2026) · The EANM Journal · doi:10.1016/j.eanmj.2026.100225
Zahner, J., Delker, A., Ells, Z., Nikolic, A. A., Holzgreve, A., Siegmund, S. C., Tiling, M., Zacherl, M. J., Berg, E. K., Aydogdu, C. D., et al. (2026) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-026-07967-3
Iravani, A., Gulati, R., Miyaoka, R. S., Rieger, A. C., Chen, D. L., Kumar, M., Erickson, M., Nega, K., Meyer, C., Lira, S., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.126.272472
Veziroglu, E., Gifani, M., Nikpanah, M., Gowda, V., Farhadi, F., & Saboury, B. (2026) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2026.08.012
Metadata
- Authors
- Okamoto, S., Thieme, A., Allmann, J., D’Alessandria, C., Maurer, T., Retz, M., Tauber, R., Heck, M. M., Wester, H.-J., Tamaki, N., Fendler, W. P., Herrmann, K., Pfob, C. H., Scheidhauer, K., Schwaiger, M., Ziegler, S., & Eiber, M.
- Affiliations
- Hokkaido University (JP)
- TUM Klinikum (DE)
- Technical University of Munich (DE)
- University of California, Los Angeles (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2016-09-22
- Volume
- 58
- Issue
- 3
- Pages
- 445-450
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- OpenAlex
- W2523192478
- Cited by
- 213
- References
- 33
- Citations by year
- 2026: 10 · 2025: 26 · 2024: 31 · 2023: 21 · 2022: 27 · 2021: 36 · 2020: 13 · 2019: 22 · 2018: 15 · 2017: 12
- FWCI
- 14.18
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-I&T, radioligand therapy, metastatic castration-resistant prostate cancer, absorbed dose, tumor dose, OLINDA/EXM, dosimetry, parotid gland, lacrimal gland, kidney dose, liver dose
- MeSH terms
- Aged, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Metabolic Clearance Rate, Neoplasm Metastasis, Organ Specificity, Radiotherapy Dosage, Retrospective Studies, Tissue Distribution, Whole-Body Counting, Treatment Outcome, Prostate-Specific Antigen, Radiopharmaceuticals, Positron-Emission Tomography, Organ Sparing Treatments, Prostatic Neoplasms, Castration-Resistant, Absorption, Radiation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
